In Vancouver, British Columbia on August 13, 2026, NervGen, a company listed on NASDAQ under the ticker NGEN, shared its financial performance for the quarter concluding on June 30, 2026. The company, a leading late-stage clinical biopharmaceutical firm specializing in innovative neuroreparative treatments for spinal cord injury (SCI) and various neurotraumatic and neurologic ailments, also disclosed recent developments in their business operations.